Clinical Trial

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease (HD).
Protocol Amendment History 1 change
minor Completion moved earlier: 2027-04-01 -> 2026-10-31 2026-08-11
Trial Details
NCT Number NCT05686551
Lead Sponsor Hoffmann-La Roche
Conditions Huntington Disease
Enrollment 301 participants
Start Date 2023-02-03
Primary Completion 2026-05-14 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10